Medtronic nets $337 million from Blackstone for diabetes research Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers AstraZeneca's Farxiga cuts risk of diabetes onset in heart failure patients Abbott's real-world data show FreeStyle Libre lowered A1c in Type 2 diabetes, with or without insulin Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2 Insulet delivers first outpatient data for its wearable, closed-loop insulin pump Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show Onduo's virtual clinic helps lower A1c in Type 2 diabetes studies Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function Featured Story | Monday, June 15, 2020 A new version of Medtronic’s advanced, hybrid closed-loop insulin delivery system showed it could help improve blood sugar control throughout the day in adolescents and young adults with Type 1 diabetes. read more |
| |
|---|
|
Top Stories Tuesday, June 16, 2020 Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data, presented during the ADA's virtual Scientific Sessions, won’t help it get on their level. read more Monday, June 15, 2020 AstraZeneca diabetes drug Farxiga last month scored a first-in-class FDA nod, winning clearance to reduce cardiovascular risks for certain heart failure patients without diabetes. Now, the British drugmaker is showing that Farxiga can actually help prevent diabetes in those patients, too. read more Monday, June 15, 2020 Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin. read more Sunday, June 14, 2020 Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to improve the insulin options out there for those who do need it. read more Tuesday, June 16, 2020 Insulet delivered the first outpatient data and at-home evaluations of its upcoming Omnipod 5—the tubeless, smartphone-controlled, wearable insulin pump formerly known as the Omnipod Horizon. read more Sunday, June 14, 2020 Eli Lilly is fighting hard to protect Trulicity's share against Novo Nordisk’s newest offerings in the GLP-1 class, and it’s breaking out real-world data to support its case. A new real-world analysis showed that at the six-month mark, patients were doing a better job sticking to Trulicity than they were to once-weekly rivals Ozempic from Novo and Bydureon BCise from AstraZeneca. read more Tuesday, June 16, 2020 Virtual diabetes clinic Onduo delivered data from three studies this week showing its coaching and monitoring platforms helped people with Type 2 diabetes better control their blood sugar while also avoiding emotional distress. read more Saturday, June 13, 2020 Sanofi’s Soliqua combines an insulin with a GLP-1 agonist, and, according to a new real-world study, delivering those two therapies simultaneously is the way to go. Starting an insulin and a GLP-1 drug around the same time gave certain Type 2 diabetes patients a significantly better shot at achieving blood sugar control than starting them more than three months apart did, real-world data showed. read more Monday, June 15, 2020 AstraZeneca’s SGLT2 diabetes drug Farxiga is already getting a speedy FDA review as a treatment for chronic kidney disease, but it’s still piling on the positive results. A new analysis showed the drug could reduce the proportion of patients with fast-declining eGFR, a common measure of kidney function. read more |
